Mohit Trikha
President & Chief Operating Officer Kivu Bioscience
Dr. Mohit (Mo) Trikha is the President and COO of Kivu Bioscience. He brings over 25 years of drug development expertise in oncology. He has been instrumental in advancing more than 40 programs from target identification to clinical trials in oncology. Previously, Mo was a venture partner at Apple Tree Partners, and also led oncology early development at AbbVie, where he oversaw the development of discovery-stage programs to clinical proof of concept, focusing on ADCs, bispecifics, and CAR-T therapies. He has contributed to the development of key drugs such as Kadcyla, Polivy, and vismodegib, and chaired collaborations with leading institutions like TeneoBio, Calibr, and The Scripps Research Institute. Earlier in his career, he held roles at Genentech, Centocor/Johnson & Johnson, and Triphase Accelerator.
Seminars
- Contextualising lessons learned from the current ADC clinical development landscape and advocating for an enhanced focus on addressing tolerability to improve ADC performance and success for patients
- Pursuing less toxic ADC development to evolve dosing to be equivalent to naked antibody therapies and expand therapeutic index
- Highlighting differentiation strategy for kinder and gentler ADC development, headlined with preclinical profile of KIVU-107 against solid tumours
